ARDX ARDELYX, INC.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1437402 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.6%
TTM net income YoY1.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR51.6%
Net income 3-yr CAGR—
Margins
Gross margin94.5%
Operating margin-7.7%
Net margin-11.8%
FCF margin-3.4%
EBITDA margin-7.1%
Returns
ROE-34.9%
ROA-10.3%
ROIC (approx.)-8.3%
Asset turnover0.87x
Leverage & solvency
Liabilities / assets72.1%
Debt / equity1.54x
Current ratio3.45x
Interest coverage-1.63x
Cash quality & payout
Operating cash flow / net income0.28x
Accruals ratio-7.4%
Payout ratio—
Capex / revenue0.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $127.66M | $120.88M | $94.47M | $125.22M | $110.33M | $97.66M | $74.11M | $116.13M |
| Cost of revenue | $4.54M | $5.76M | $4.81M | $10.85M | $3.98M | $12.40M | $12.30M | $18.26M |
| Gross profit | $123.12M | $115.12M | $89.66M | $114.37M | $106.35M | $85.26M | $61.81M | $97.86M |
| R&D expense | $25.20M | $26.10M | $20.19M | $22.86M | $18.07M | $15.67M | $14.94M | $13.67M |
| SG&A expense | $93.89M | $101.44M | $102.27M | $86.41M | $83.61M | $83.99M | $83.22M | $76.07M |
| Operating income | $4.02M | -$12.43M | -$32.79M | $5.10M | $4.67M | -$14.39M | -$36.35M | $8.12M |
| Interest expense | $5.88M | $4.96M | $5.60M | $5.76M | $5.80M | $4.36M | $4.19M | $3.97M |
| Pretax income | -$647,000 | -$16.61M | -$37.60M | -$400,000 | -$867,000 | -$19.08M | -$40.28M | $4.68M |
| Income tax | $90,000 | $110,000 | $8,000 | $7,000 | $102,000 | $1,000 | $859,000 | $35,000 |
| Net income | -$737,000 | -$16.72M | -$37.60M | -$407,000 | -$969,000 | -$19.08M | -$41.14M | $4.64M |
| EBITDA | $4.64M | -$11.82M | -$31.88M | $6.02M | $5.57M | -$13.76M | -$35.75M | $8.64M |
| EPS (basic) | 0.00 | -0.07 | -0.15 | — | 0.00 | -0.08 | -0.17 | — |
| EPS (diluted) | 0.00 | -0.07 | -0.15 | — | 0.00 | -0.08 | -0.17 | — |
| Weighted avg. shares (diluted) | 250.01M | 248.07M | 245.86M | — | 241.91M | 239.93M | 238.62M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $46.32M | $97.19M | $31.21M | $68.00M | $42.72M | $90.05M | $30.81M | $64.93M |
| Short-term investments | $239.02M | $184.64M | $206.87M | $196.69M | $199.99M | $148.41M | $183.14M | $185.17M |
| Receivables | $93.44M | $100.35M | $82.84M | $71.85M | $76.61M | $62.55M | $46.47M | $57.70M |
| Inventory | $157.56M | $138.99M | $128.03M | $123.11M | $129.36M | $123.26M | $105.88M | $91.18M |
| Current assets | $441.39M | $441.93M | $381.87M | $382.32M | $367.99M | $351.57M | $312.69M | $356.45M |
| PP&E, net | $1.57M | $1.78M | $2.00M | $2.18M | $2.07M | $2.14M | $1.67M | $1.50M |
| Total assets | $587.52M | $575.89M | $504.51M | $501.60M | $486.17M | $466.77M | $410.19M | $435.75M |
| Current liabilities | $127.81M | $132.22M | $109.57M | $88.61M | $83.39M | $81.72M | $75.84M | $77.83M |
| Long-term debt | $252.36M | $251.82M | $203.52M | $202.83M | $202.14M | $201.45M | $151.30M | $150.85M |
| Total debt | $252.36M | $251.82M | $203.52M | $202.83M | $202.14M | $201.45M | $151.30M | $150.85M |
| Total liabilities | $423.48M | $426.88M | $355.88M | $334.65M | $331.89M | $327.24M | $264.52M | $262.46M |
| Shareholders' equity | $164.05M | $149.01M | $148.62M | $166.95M | $154.28M | $139.53M | $145.68M | $173.29M |
| Net debt | $206.04M | $154.63M | $172.31M | $134.84M | $159.42M | $111.40M | $120.49M | $85.92M |
| Shares outstanding | 251.03M | 249.15M | 246.97M | 244.35M | 242.97M | 240.77M | 239.20M | 238.02M |
| Cash flow statement | ||||||||
| Operating cash flow | $2.17M | -$6.40M | -$32.24M | $20.95M | $365,000 | -$25.34M | -$38.46M | $9.81M |
| Capital expenditure | $0 | $13,000 | $69,000 | $361,000 | $156,000 | $650,000 | $325,000 | $593,000 |
| Free cash flow | $2.17M | -$6.41M | -$32.31M | $20.59M | $209,000 | -$25.99M | -$38.78M | $9.22M |
| Investing cash flow | -$54.00M | $22.66M | -$9.99M | $3.78M | -$50.51M | $34.92M | $2.85M | -$41.62M |
| Financing cash flow | $959,000 | $49.72M | $5.44M | $557,000 | $2.81M | $49.66M | $1.48M | $49.31M |
| Depreciation & amortization | $621,000 | $604,000 | $915,000 | $921,000 | $905,000 | $631,000 | $602,000 | $515,000 |
| Stock-based compensation | $15.10M | $15.32M | $14.16M | $12.45M | $12.74M | $11.69M | $12.09M | $9.86M |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.